154044-13-0

Usage

Uses

Used in Fragrance and Flavor Industry:
Ethyl 5-(4-hydroxyphenyl)pentanoate is utilized as a fragrance and flavoring agent due to its distinctive sweet, fruity scent. It is incorporated into a range of products such as perfumes, cosmetics, and food flavorings to enhance their sensory appeal.
Used in Pharmaceutical Research:
Ethyl 5-(4-hydroxyphenyl)pentanoate is also being explored for its potential pharmacological properties. It has been studied for its anti-inflammatory and antioxidant effects, indicating its possible use in the development of new therapeutic agents for various health conditions.

InChI:InChI=1/C13H18O3/c1-2-16-13(15)6-4-3-5-11-7-9-12(14)10-8-11/h7-10,14H,2-6H2,1H3

Upstream product

• 64-17-5 ethanol 
• 4654-08-4 5-(4'-hydroxyphenyl)pentanoic acid 
• 7508-04-5 5-(4-methoxyphenyl)pentanoic acid 
• 100-66-3 methoxybenzene 
• 108-55-4 glutaric anhydride, 
• 4609-10-3 5-(4-methoxyphenyl)-5-oxopentanoic acid 

Downstream Products

• 868850-06-0 5-{4-[(3-fluorobenzyl)oxy]phenyl}pentanoic acid 

Relevant academic research and scientific papers

Structural determinants of 4-chloro-m-cresol required for activation of ryanodine receptor type 1

4-Chloro-m-cresol (4-CmC) is a clinically relevant activator of the intracellular Ca2+ release channel, the ryanodine receptor isoform 1 (RyR1). In this study, the chemical moieties on the 4-CmC molecule required for its activation of RyR1 were

Design and Structural Optimization of Dual FXR/PPARδActivators

Nonalcoholic steatohepatitis (NASH) is considered as severe hepatic manifestation of the metabolic syndrome and has alarming global prevalence. The ligand-activated transcription factors farnesoid X receptor (FXR) and peroxisome proliferator-activated receptor (PPAR) δhave been validated as molecular targets to counter NASH. To achieve robust therapeutic efficacy in this multifactorial pathology, combined peripheral PPAR?-mediated activity and hepatic effects of FXR activation appear as a promising multitarget approach. We have designed a minimal dual FXR/PPARδactivator scaffold by rational fusion of pharmacophores derived from selective agonists. Our dual agonist lead compound exhibited weak agonism on FXR and PPARδand was structurally refined to a potent and balanced FXR/PPARδactivator in a computer-aided fashion. The resulting dual FXR/PPARδmodulator comprises high selectivity over related nuclear receptors and activates the two target transcription factors in native cellular settings.

Racemic total synthesis of dactyloidin and demethyldactyloidin through the dl-proline-catalyzed Knoevenagel condensation/[4 + 2] cycloaddition cascade

An efficient approach towards the first racemic total synthesis of dactyloidin (2) and demethyldactyloidin (3) is described. Their oxygen-bridged tricyclic ketal systems were rapidly constructed by using a remarkable biomimetic Knoevenagel condensation/[4 + 2] cycloaddition cascade as the critical strategy and the 1,5-dicarbonyl segment was assembled by Grignard addition.